CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT
Aim. To investigate effectiveness and safety of trimetazidine MB in the complex treatment of stable angina. In total, 90 patients were examined – 57 women and 33 men aged 48-70 years (mean age 61,4 ± 6,03 years). All participants received trimetazidine MB (Deprenorm MB) for 3 months (35 mg twice per...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2009-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1401 |
| Summary: | Aim. To investigate effectiveness and safety of trimetazidine MB in the complex treatment of stable angina. In total, 90 patients were examined – 57 women and 33 men aged 48-70 years (mean age 61,4 ± 6,03 years). All participants received trimetazidine MB (Deprenorm MB) for 3 months (35 mg twice per day). The treatment was associated with reduced angina attack incidence and decreased dose of isosorbide dinitrate, taken during angina attacks. Functional class (FC) of angina was also reduced. Conclusion. Deprenorm MB could be recommended for complex treatment of the patients with coronary heart disease and stable effort angina, who already receive standard anti-anginal therapy. |
|---|---|
| ISSN: | 1560-4071 2618-7620 |